Recent Advances in Gene Therapy of Endometriosis

Anastasia Shubina, Anastasia N Shubina, Shubina AN, Egorova AA, Anna A Egorova, Anna Egorova, В. С. Баранов, Baranov VS, Vladislav S Baranov, Anton V Kiselev, Anton Kiselev, Kiselev AV
Recent patents on DNA & gene sequences · 2014 · vol. 7(3) , pp. 169–178 · doi:10.2174/18722156113079990021 · PMID:23862716 · W2110652303
review OA: closed CC0 ⤵ 13 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This review summarizes the pathogenesis of endometriosis and highlights current gene therapy approaches for this gynecological disorder.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-10 · read from full text ⓘ

This review summarizes endometriosis as a common reproductive-age gynecological disease and outlines its proposed pathogenesis, including altered steroid metabolism, immune abnormalities with inflammation, increased angiogenic activity in peritoneal fluid, impaired recognition of ectopic endometrial cells, and contributions from genetic, anatomical, and environmental factors. It notes that although multiple surgical and medical treatments exist, complete resolution remains unachieved. The key focus is to describe current gene therapy approaches by linking them to the disease’s pathogenetic mechanisms, while acknowledging that gene therapy is presented as having promising potential based on ongoing research. This paper is centrally about endometriosis — it reviews the pathogenetic background and highlights current gene therapy approaches for treating endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a gynecological disease that affects up to 10%-15% of all reproductive-age women worldwide. It is characterized by the presence of endometrial tissues outside the uterine cavity. Endometriosis is a complex disease; its pathogenesis includes altered steroid metabolism and immune system abnormalities such as inflammation, increased angiogenic activity in the peritoneal fluid and impaired recognition of ectopic endometrial cells. The development of endometriosis also depends on genetic, anatomical and environmental factors. Numerous surgical and medical approaches to treat endometriosis have been developed to date. However, complete resolution of the problem has not been achieved so far. Gene therapy holds exciting promise for the treatment of numerous disorders and current studies have indicated it can also be applied to endometriosis. The focus of this review is to summarize the pathogenetic background of the disease and to highlight current gene therapy approaches for this common gynecological disorder.
Full text 1,129 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Endometriosis is a gynecological disease that affects up to 10%-15% of all reproductive-age women worldwide. It is characterized by the presence of endometrial tissues outside the uterine cavity. Endometriosis is a complex disease; its pathogenesis includes altered steroid metabolism and immune system abnormalities such as inflammation, increased angiogenic activity in the peritoneal fluid and impaired recognition of ectopic endometrial cells. The development of endometriosis also depends on genetic, anatomical and environmental factors. Numerous surgical and medical approaches to treat endometriosis have been developed to date. However, complete resolution of the problem has not been achieved so far. Gene therapy holds exciting promise for the treatment of numerous disorders and current studies have indicated it can also be applied to endometriosis. The focus of this review is to summarize the pathogenetic background of the disease and to highlight current gene therapy approaches for this common gynecological disorder.

Keywords

Angiogenesis, endometriosis, gene delivery, gene therapy, inflammation. 68

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Genetic Therapy Aryl Hydrocarbon Hydroxylases Aryl Hydrocarbon Hydroxylases Aryl Hydrocarbon Hydroxylases Cyclin-Dependent Kinase Inhibitor Proteins Cyclin-Dependent Kinase Inhibitor Proteins Cyclin-Dependent Kinase Inhibitor Proteins Cytochrome P-450 CYP2C19 Endometriosis Endometriosis Female Homeodomain Proteins Homeodomain Proteins Homeodomain Proteins Humans Neovascularization, Physiologic Neovascularization, Physiologic Patents as Topic RNA Interference

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (13)

Source provenance

europepmc
last seen: 2026-08-03T06:10:56.557307+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:53.335890+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK